News | News By Subject | News by Disease News By Date | Search News

Rheumatoid arthritis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Two Deaths Hit AbbVie (ABBV)'s Late-Stage RA Study     9/13/2017
7 PDUFA Dates to Mark on Your Calendars for September     9/7/2017
FDA Advisory Panel Votes Against Approval Of Johnson & Johnson (JNJ)’s Sirukumab     8/4/2017
FDA Raises Big Safety Concerns With Johnson & Johnson (JNJ)'s Arthritis Drug Sirukumab     8/1/2017
Blood Clot Fears Delay Eli Lilly (LLY), Incyte (INCY)'s Potential Rheumatoid Arthritis Blockbuster, Stocks Fall     7/25/2017
Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space     7/20/2017
Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug     7/6/2017
Hundreds of Patient Deaths Linked to Roche (RHHBY)'s RA Drug Actemra     6/12/2017
Market Just Got More Crowded as Regeneron (REGN), Sanofi (SNY)'s New RA Drug Wins FDA Approval     5/24/2017
FDA Just Rejected Eli Lilly (LLY), Incyte (INCY)'s Rheumatoid Arthritis Drug Baricitinib     4/18/2017
Success of Pfizer (PFE)’s Humira Biosimilar for Rheumatoid Arthritis in Phase III Bodes Well for Its Strong Biosimilar Pipeline     1/23/2017
Going Up Against AbbVie (ABBV)'s Humira, Johnson & Johnson (JNJ) Presents Less-Than-Stellar Phase III Data     11/14/2016
OUCH! FDA Spurns Regeneron (REGN), Sanofi (SNY)'s RA Drug Over Plant Deficiencies     11/1/2016
Deficiencies Found at Manufacturing Site Could Delay Approval of Sanofi Genzyme (SNY)'s Next Blockbuster     10/31/2016
AbbVie (ABBV) Abandons Arthritis Pact With Ablynx (ABLYF)     10/20/2016

News from Around the Web
Eli Lilly (LLY) Gives No New Information On Rheumatoid Arthritis Drug Delay     4/26/2017
How AbbVie (ABBV), Gilead (GILD), Pfizer (PFE) Are All Gaining From Eli Lilly (LLY)'s RA Rejection Pain     4/18/2017
Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, University of Amsterdam Study Shows     7/5/2016
Green Tea Compound May Block Rheumatoid Arthritis, Washington State University Study     2/17/2016
Occupational Textile Dust Exposure Linked To Rheumatoid Arthritis, Study Published In BMJ     1/15/2016
Your Diet May Determine Rheumatoid Arthritis Risk, Brigham and Women's Hospital Study     11/9/2015
Could Oral Contraceptives Help Ease Rheumatoid Arthritis? Rheumatism Research Centre Study     8/31/2015
Drug Flops From 2004 Haunt AstraZeneca PLC (AZN) Investors     5/23/2014
Chinese Herb As Effective As Arthritis Pain Drug, Annals of the Rheumatic Diseases Reveals     4/16/2014
Extra Pounds Linked to Rheumatoid Arthritis Risk in Women, Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health Reveals     11/12/2012
Rheumatoid Arthritis Drugs May Help Curb Diabetes Development, Journal of the American Medical AssociationStudy Finds     6/22/2011
EULAR: Rituximab Plus Other Biologics Safe in RA     6/1/2011
Study Identifies Novel Role for a Protein That Could Lead to New Treatments for Rheumatoid Arthritis, Hospital for Special Surgery Study     5/23/2011
Lupus, Rheumatoid Arthritis May Raise Risk of Abnormal Heart Rhythm, University of Arkansas for Medical Sciences Study     5/9/2011
Recent Rituximab Trial with TNF Inhibitors Reports No New Safety Risks in Patients with Rheumatoid Arthritis, Desert Medical Advances Study     3/8/2011

Press Releases
CEL-SCI (CVM) Announces $1.5 Million NIH SBIR Grant To Support Development Of Rheumatoid Arthritis Vaccine     9/19/2017
Sandoz Proposed Biosimilar Rituximab Accepted For Review By The FDA     9/12/2017
Rejected Only A Few Weeks Ago, Eli Lilly (LLY) Will Resubmit NDA App For Potential RA Blockbuster In Just 5 Months     8/30/2017
Coherus Announces Positive Topline Results For Clinical Pharmacokinetic Bioequivalence Study For CHS-1420 (Humira® Biosimilar Candidate) Versus European Marketed Humira In Healthy Subjects     8/28/2017
IMRALDI, Biogen (BIIB)’s Adalimumab Biosimilar Referencing Humira, Is Approved In The European Union     8/25/2017
Samsung Bioepis First To Obtain European Commission (EC) Approval For A Third Anti-TNF-? Biosimilar With Imraldi (Adalimumab)     8/25/2017
Can-Fite BioPharma (CFBI) Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson     8/7/2017
Merck & Co. (MRK) Announces U.S. Launch Of RENFLEXIS (Infliximab-Abda), A Biosimilar Of Remicade, For All Eligible Indications     7/24/2017
Eli Lilly (LLY) Release: Japan Ministry of Health, Labor And Welfare (MHLW) Grants Marketing Approval For Olumiant (Baricitinib) For The Treatment Of Rheumatoid Arthritis     7/5/2017
Regeneron (REGN) And Sanofi (SNY) Announce Approval Of Kevzara (Sarilumab) To Treat Adult Patients With Moderately To Severely Active Rheumatoid Arthritis In The European Union     6/27/2017
Ampio Pharmaceuticals, Inc. (AMPE) Injects First Patient In Final Pivotal Clinical Trial For Ampion BLA     6/22/2017
Eli Lilly (LLY) Release: New Safety And Long-Term Efficacy Data From Baricitinib Clinical Trials In Patients With Moderate-To-Severe Rheumatoid Arthritis Presented At EULAR 2017     6/16/2017
Janssen-Cilag International NV (JNJ) Presents Long Term Phase III Efficacy And Safety Data Of Sirukumab In Rheumatoid Arthritis Patients Who Had An Inadequate Response And/Or Who Were Intolerant To Anti-TNFs     6/14/2017
Eli Lilly (LLY) To Present New Data On Olumiant (Baricitinib) In Rheumatoid Arthritis And Taltz (Ixekizumab) In Psoriatic Arthritis At The Annual European Congress Of Rheumatology (EULAR 2017)     6/14/2017
Can-Fite BioPharma (CFBI) Concludes Successful Clinical Investigator Meeting For Its Acrobat Phase III Trial Of Piclidenoson In The Treatment Of Rheumatoid Arthritis     6/8/2017

//-->